Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - AzurRx BioPharma, Inc. | azrx8k_may292018.htm |
Exhibit 99.1
AzurRx Announces Appointment of Dr. James Pennington as Chief
Medical Officer
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.
(NASDAQ:AZRX) (“AzurRx” or the
“Company”), a company specializing in the development
of non-systemic, recombinant therapies
for gastrointestinal diseases, today announced the appointment
of Dr. James Pennington as the Company’s Chief Medical
Officer.
“We are delighted to welcome Jim to the senior management
team as we rapidly advance our clinical programs,” commented
Thijs Spoor, CEO of AzurRx BioPharma. “Jim is a highly
accomplished pharmaceutical industry executive with extensive
medical and clinical experience, as well as hands-on experience in
regulatory affairs. His appointment is timely as 2018 is shaping up
to be a pivotal year for AzurRx, with a number of upcoming and
potentially value enhancing milestones including the initiation of
the MS1819 Phase 2 study in cystic fibrosis patients and the filing
of the investigational drug application (“IND”) in the
U.S. for MS1819. We look forward to Jim’s leadership and
contributions as these programs move forward.”
“I am excited to join the AzurRx team at this exciting time
for the Company,” said Dr. Pennington, “We look forward
to initiating a cystic fibrosis study later this year. MS1819,
which has generated promising interim results in the ongoing study
in chronic pancreatitis patients, addresses a billion-dollar market
in exocrine pancreatic insufficiency. It has the potential to
become best in class due to the high pill burden, patient
compliance issues, and manufacturing/supply chain challenges of the
current animal-derived therapies.”
Dr. Pennington brings over 30 years of experience in the
pharmaceutical industry. He served as Vice President at Bayer
Corporation where, under his direct supervision, Bayer received ten
product approvals from the U.S. Food & Drug Administration
(“FDA”) and ten product approvals from foreign
regulatory authorities. Dr. Pennington also held senior positions
at multiple therapeutics companies, including CMO roles at Anthera
Pharmaceuticals and CoTherix Inc. and Senior VP of Research,
Development and Clinical Affairs at Alpha Therapeutics Corp. Dr.
Pennington has participated in many FDA pre-IND meetings and has
also participated in several FDA Advisory Panel meetings. He has
served on various editorial boards as well as professional
societies, such as the American Association of the Advancement of
Science. He is involved in academia and is currently Clinical
Professor of Medicine at the University of California in San
Francisco. Dr. Pennington holds a B.A. from the University of
Oregon and an M.D. from the University of Oregon Medical School and
is Board Certified in internal medicine and infectious
diseases.
About AzurRx BioPharma, Inc.
AzurRx BioPharma aims to become a leader in developing
non-systemic, recombinant protein therapies for the treatment of
gastrointestinal diseases and infectious diseases. MS1819
recombinant lipase for exocrine pancreatic insufficiency is the
Company’s lead development program, and additional early
stage research is being conducted for the prevention of
hospital-acquired infection. The Company is headquartered in New
York, NY, with scientific operations based in Langlade,
France.
Company website address: www.azurrx.com
Forward-Looking Statements
This press release may contain certain statements relating to
future results which are forward-looking statements. These
statements are not historical facts, but instead represent only the
Company’s belief regarding future events, many of which, by
their nature, are inherently uncertain and outside of the
Company’s control. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements. Additional
information concerning the Company and its business, including
factors that potentially could materially affect the
Company’s financial results, are contained in the
Company’s filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become
aware.
For more Information:
AzurRx BioPharma, Inc.,
760 Parkside Avenue
Suite 304
Brooklyn, NY 11226
Phone: (646)-699-7855
info@azurrx.com